Alexion Pharmaceuticals Inc. (ALXN)

108.37
NASDAQ : Health Technology
Prev Close 105.89
Day Low/High 106.02 / 108.59
52 Wk Low/High 92.56 / 141.86
Avg Volume 2.24M
Exchange NASDAQ
Shares Outstanding 221.29M
Market Cap 23.43B
EPS 0.30
P/E Ratio 7.52
Div & Yield N.A. (N.A)

Latest News

Stocks Finish Higher as Investors Digest Mixed Boeing and Caterpillar Earnings

Stocks Finish Higher as Investors Digest Mixed Boeing and Caterpillar Earnings

Stocks finish higher Wednesday as the Dow Jones Industrial Average got a boost from Boeing and Caterpillar, while Texas Instruments' earnings miss pulls down the chip sector.

Alexion Rises After Drug Developer Beats Earnings Expectations

Alexion Rises After Drug Developer Beats Earnings Expectations

Sales of Soliris, the Boston-based pharma company's treatment for a rare blood disorder, rises 12% in the third quarter to $990.5 million.

Big Biotech Receives Some Needed Shots in the Arm

Big Biotech Receives Some Needed Shots in the Arm

Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.

Alexion Reports Third Quarter 2019 Results

Alexion Reports Third Quarter 2019 Results

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2019.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

Alexion Receives FDA Approval For ULTOMIRIS® (ravulizumab-cwvz) For Atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Receives FDA Approval For ULTOMIRIS® (ravulizumab-cwvz) For Atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.

NEW YORK, Oct. 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Achillion Pharmaceuticals, Inc.

Alexion Pharmaceuticals to Acquire Achillion in $930 Million Deal

Alexion Pharmaceuticals to Acquire Achillion in $930 Million Deal

Alexion is seeking to expand its pipeline of rare disease treatments through the acquisition.

Achillion (ACHN) Alert: Johnson Fistel Investigates Proposed Sale Of Achillion Pharmaceuticals; Are Shareholders Getting A Fair Deal?

Achillion (ACHN) Alert: Johnson Fistel Investigates Proposed Sale Of Achillion Pharmaceuticals; Are Shareholders Getting A Fair Deal?

SAN DIEGO, Oct. 16, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Achillion Pharmaceuticals, Inc.

Alexion To Acquire Achillion

Alexion To Acquire Achillion

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Achillion Pharmaceuticals, Inc.

Here Are Several Promising Rare Disease Stocks

Here Are Several Promising Rare Disease Stocks

These small biotech concerns are undervalued.

(Photo: Business Wire)

(Photo: Business Wire)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of Tanisha Carino, Ph.

Alexion And Stealth Announce Agreement For Option To Co-Develop And Commercialize Late-Stage Therapy For Mitochondrial Diseases

Alexion And Stealth Announce Agreement For Option To Co-Develop And Commercialize Late-Stage Therapy For Mitochondrial Diseases

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Stealth BioTherapeutics Corp (NASDAQ:MITO) today announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases.

I'm Unapologetically Overweight in These 2 Sectors

I'm Unapologetically Overweight in These 2 Sectors

The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.

Alexion To Report Third Quarter 2019 Results On Wednesday, October 23, 2019

Alexion To Report Third Quarter 2019 Results On Wednesday, October 23, 2019

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2019 before the US financial markets open on October 23, 2019.

3 Biotech Plays That Would Work as Covered Calls

3 Biotech Plays That Would Work as Covered Calls

The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.

Alexion Shares Slide After Departure of Chief Financial Officer

Alexion Shares Slide After Departure of Chief Financial Officer

Paul Clancy will step down later this year and be succeeded by chief strategy and business officer, Aradhana Sarin.

Alexion Announces CFO Succession

Alexion Announces CFO Succession

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans for the transition of Executive Vice President and Chief Financial Officer Paul Clancy later this year.

Alexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine

Alexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and BridgeBio Pharma, Inc.

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

Alexion To Present At The 17th Annual Morgan Stanley Global Healthcare Conference

Alexion To Present At The 17th Annual Morgan Stanley Global Healthcare Conference

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 17th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9th, 2019 at 8:45 a.

Alexion Announces Upcoming Data Presentations At 35th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis

Alexion Announces Upcoming Data Presentations At 35th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five abstracts from the Phase 3 PREVENT study of SOLIRIS ® (eculizumab) in neuromyelitis optica spectrum disorder (NMOSD) have been accepted for presentation at the 35 th Congress of the...

Alexion To Present At The 14th Annual Citi Biotech Conference

Alexion To Present At The 14th Annual Citi Biotech Conference

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 14th Annual Citi Biotech Conference in Boston, MA on Wednesday, September 4th, 2019 at 12:00 p.

European Commission Approves SOLIRIS® (eculizumab) For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

European Commission Approves SOLIRIS® (eculizumab) For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission (EC) has approved the extension of the current marketing authorization of SOLIRIS ® (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder...

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Recent speculation that the biotech giant would buy Alexion had boosted ALXN's shares. But Amgen just agreed to lay out $13.4 billion for Celgene's psoriasis drug.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

TheStreet Quant Rating: C+ (Hold)